Efficacy and Safety of PD-1/L1 Inhibitors Combined with Anlotinib versus PD-1 /L1 Inhibitors Combined with Bevacizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients: A Comparative Cohort Study.

IF 2.3 4区医学 Q3 ONCOLOGY Current cancer drug targets Pub Date : 2025-01-16 DOI:10.2174/0115680096338045241117161228

Xiaobing Li, De Wu, Yi Peng, Jing Tang, Yuebing Wu

{"title":"Efficacy and Safety of PD-1/L1 Inhibitors Combined with Anlotinib versus PD-1 /L1 Inhibitors Combined with Bevacizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients: A Comparative Cohort Study.","authors":"Xiaobing Li, De Wu, Yi Peng, Jing Tang, Yuebing Wu","doi":"10.2174/0115680096338045241117161228","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to compare the efficacy and safety of PD-1/L1 inhibitors combined with anlotinib versus PD-1/L1 inhibitors combined with bevacizumab as second-line treatments for advanced NSCLC patients.Methods: A retrospective analysis was carried out on data from advanced NSCLC patients who received either PD-1/L1 inhibitors combined with anlotinib or PD-1/L1 inhibitors combined with bevacizumab as second-line therapy. Clinical outcomes, including Overall Survival (OS), Progression-Free Survival (PFS), Objective Response Rate (ORR), Disease Control Rate (DCR), and Adverse Events (AEs), were compared between the two treatment groups.Results: The results revealed that patients receiving PD-1/L1 inhibitors combined with anlo-tinib exhibited better efficacy compared to patients receiving PD-1/L1 inhibitors combined with bevacizumab (mPFS 5.0m vs. 4.0m, mOS 10.0m vs. 8.0m, ORR 31.25% vs. 17.14%, DCR 65.63% vs. 45.71%). Additionally, both treatment regimens were generally well-tolerated, with most adverse events being manageable and of mild to moderate severity. However, compared with patients receiving PD-1/L1 inhibitors combined with bevacizumab, those receiving PD-1/L1 inhibitors combined with anlotinib have higher incidence rates of certain adverse reactions (hypertension: 34.38% vs. 17.14%, proteinuria: 25% vs. 14.29%), implying that drug combinations of the same treatment modality may exhibit differences in efficacy and adverse reactions.Conclusion: In this comparative study, PD-1/L1 inhibitors combined with anlotinib demonstrated superior efficacy compared to PD-1/L1 inhibitors combined with bevacizumab as second-line therapy for advanced NSCLC patients, with a manageable safety profile. These findings provide valuable clinical evidence for guiding treatment decisions in this patient population.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096338045241117161228","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to compare the efficacy and safety of PD-1/L1 inhibitors combined with anlotinib versus PD-1/L1 inhibitors combined with bevacizumab as second-line treatments for advanced NSCLC patients.

Methods: A retrospective analysis was carried out on data from advanced NSCLC patients who received either PD-1/L1 inhibitors combined with anlotinib or PD-1/L1 inhibitors combined with bevacizumab as second-line therapy. Clinical outcomes, including Overall Survival (OS), Progression-Free Survival (PFS), Objective Response Rate (ORR), Disease Control Rate (DCR), and Adverse Events (AEs), were compared between the two treatment groups.

Results: The results revealed that patients receiving PD-1/L1 inhibitors combined with anlo-tinib exhibited better efficacy compared to patients receiving PD-1/L1 inhibitors combined with bevacizumab (mPFS 5.0m vs. 4.0m, mOS 10.0m vs. 8.0m, ORR 31.25% vs. 17.14%, DCR 65.63% vs. 45.71%). Additionally, both treatment regimens were generally well-tolerated, with most adverse events being manageable and of mild to moderate severity. However, compared with patients receiving PD-1/L1 inhibitors combined with bevacizumab, those receiving PD-1/L1 inhibitors combined with anlotinib have higher incidence rates of certain adverse reactions (hypertension: 34.38% vs. 17.14%, proteinuria: 25% vs. 14.29%), implying that drug combinations of the same treatment modality may exhibit differences in efficacy and adverse reactions.

Conclusion: In this comparative study, PD-1/L1 inhibitors combined with anlotinib demonstrated superior efficacy compared to PD-1/L1 inhibitors combined with bevacizumab as second-line therapy for advanced NSCLC patients, with a manageable safety profile. These findings provide valuable clinical evidence for guiding treatment decisions in this patient population.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PD-1/L1抑制剂联合安洛替尼与PD-1/L1抑制剂联合贝伐单抗二线治疗晚期非小细胞肺癌患者的疗效和安全性：一项比较队列研究

背景：本研究旨在比较PD-1/L1抑制剂联合安洛替尼与PD-1/L1抑制剂联合贝伐单抗作为二线治疗晚期NSCLC患者的疗效和安全性。方法：回顾性分析接受PD-1/L1抑制剂联合安洛替尼或PD-1/L1抑制剂联合贝伐单抗作为二线治疗的晚期NSCLC患者的数据。比较两组患者的临床结果，包括总生存期（OS）、无进展生存期（PFS）、客观缓解率（ORR）、疾病控制率（DCR）和不良事件（ae）。结果：结果显示，PD-1/L1抑制剂联合anlo-tinib治疗患者的疗效优于PD-1/L1抑制剂联合贝伐单抗治疗患者（mPFS 5.0m vs. 4.0m, mOS 10.0m vs. 8.0m, ORR 31.25% vs. 17.14%, DCR 65.63% vs. 45.71%）。此外，两种治疗方案通常耐受性良好，大多数不良事件是可控的，严重程度为轻度至中度。然而，与PD-1/L1抑制剂联合贝伐单抗的患者相比，PD-1/L1抑制剂联合安洛替尼的某些不良反应发生率更高（高血压：34.38% vs. 17.14%，蛋白尿：25% vs. 14.29%），这意味着相同治疗方式的药物组合可能在疗效和不良反应上存在差异。结论：在这项比较研究中，PD-1/L1抑制剂联合anlotinib作为晚期NSCLC患者的二线治疗，与PD-1/L1抑制剂联合贝伐单抗相比，显示出更高的疗效，并且具有可控的安全性。这些发现为指导该患者群体的治疗决策提供了有价值的临床证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.